Abstract
Every year the incidence of non-small cell lung cancer (NSCLC) is increasing. Despite various therapeutic approaches and development of new diagnostic techniques, NSCLC still has an extremely poor prognosis as the result of resistance of cancer cells to conventional therapy. Finding of new simple and minimally invasive diagnostic methods of NSCLC is an actual aim for practical medicine. Development and designing of new effective anticancer therapeutic schemas and strategies are necessary for the decrease of morbidity and mortality rate from NSCLC. MicroRNAs are a class of 18–31 nt small non-coding RNAs (sncRNAs), which are involved in all processes in human organism. MicroRNAs control pathomechanisms of transformation of normal cells into cancerous cells and regulate signaling pathways of immune defense escape. In this chapter we reviewed recent research literature regarding NSCLC diagnosis, prognosis for response on therapy, and new therapeutic approaches in a view of using microRNAs.
This is a preview of subscription content, log in via an institution to check access.
References
Ahmadzadeh M, Johnson LA, Heemskerk B et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 4(8):1537–1544. https://doi.org/10.1182/blood-2008-12-195792
Ahn YH, Ko YH (2020) Diagnostic and therapeutic implications of microRNAs in non-small cell lung cancer. Int J Mol Sci 21(22):8782. https://doi.org/10.3390/ijms21228782
Astor L (2021) Study shows increase in lung cancer mortality, decrease in diagnosis during COVID-19 pandemic. Cancer. Network. https://www.cancernetwork.com/view/study-shows-increase-in-lung-cancer-mortality-decrease-in-diagnosis-during-covid-19-pandemic
Barron L et al (2010) Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol 185:6426–6430. https://doi.org/10.4049/jimmunol.0903940
Boldrini L, Giordano M, Niccoli C et al (2017) Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. Cancer Cell Int 17:105. https://doi.org/10.1186/s12935-017-0474-y
Brahmer JR, Pardoll DM (2013) Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 1(2):85–91. https://doi.org/10.1158/2326-6066.CIR-13-0078
Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98–106. https://doi.org/10.1097/COC.0000000000000239
Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L (2015) Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol 10(7):974–984. https://doi.org/10.1097/JTO.0000000000000551
Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Pass HI (2013) MicroRNAs derived from circulating exosomes as non-invasive biomarkers for screening and diagnose lung cancer. J Thorac Oncol 8(9):1156–1162. https://doi.org/10.1097/JTO.0b013e318299ac32
Cellini F, Morganti AG, Genovesi D, Silvestris N, Valentini V (2014) Role of microRNA in response to ionizing radiations: evidences and potential impact on clinical practice for radiotherapy. Molecules 19(4):5379–5401. https://doi.org/10.3390/molecules19045379
Chakraborty C, Sharma AR, Sharma G, Lee SS (2021) Therapeutic advances of miRNAs: a preclinical and clinical update. J Adv Res 28:127–138. https://doi.org/10.1016/j.jare.2020.08.012
Chan LW, Wang FF, Cho WC (2012) Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer. Curr Top Med Chem 12:920–926. https://doi.org/10.2174/156802612800166747
Chatterjee A, Chattopadhyay D, Chakrabarti G (2014) miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One 9(4):e95716. https://doi.org/10.1371/journal.pone.0095716
Chatterjee A, Chattopadhyay D, Chakrabarti G (2015) MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal 27(2):189–203. https://doi.org/10.1016/j.cellsig.2014.11.023
Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125:3384–3391. https://doi.org/10.1172/JCI80011
Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303:83–86. https://doi.org/10.1126/science.1091903
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX (2014a) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intra-tumoral immunosuppression. Nat Commun 5:5241. https://doi.org/10.1038/ncomms6241
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W et al (2014b) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241. https://doi.org/10.1038/ncomms6241
Chen X, Xu Y, Liao X et al (2016) Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumour Biol 37(9):11927–11936. https://doi.org/10.1007/s13277-016-5052-8
Cohen S, Carpenter G, King L Jr (1981) Epidermal growth factor-receptor-protein kinase interactions. Prog Clin Biol Res 66:557–567
Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW (2016) PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 108. https://doi.org/10.1093/jnci/djv303
Cox DN, Chao A, Lin H (2000) Piwi encodes a nucleoplasmic factor whose activity modulates the number and division rate of germline stem cells. Development 127:503–514. https://doi.org/10.1242/dev.127.3.503
Cox DN, Chao A, Baker J, Chang L, Qiao D, Lin H (2008) A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev 12:3715–3727
Cruz LO, Hashemifar SS, Wu CJ, Cho S, Nguyen DT, Lin LL, Khan AA, Lu LF (2017) Excessive expression of miR-27 impairs Treg-mediated immunological tolerance. J Clin Invest 127:530–542. https://doi.org/10.1172/JCI88415
Crvenkova S (2018) Survival and side effects in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy. OA Macedonian J Med Sci 6(12):2323–2327. https://doi.org/10.3889/oamjms.2018.490
Cui SY, Huang JY, Chen YT et al (2013a) Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma. Mol Cancer Res 11(7):699–713. https://doi.org/10.1158/1541-7786.MCR-13-0019-T
Cui E-H, Li H-J, Hua F et al (2013b) Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin 34(2):309–313. https://doi.org/10.1038/aps.2012.125
Cui W, Milner-Watts C, Saith S et al (2021) 180P Incidence of brain metastases (BM) in newly diagnosed stage 4 NSCLC during COVID-19. European Lung Cancer Virtual Congress 2021 (25–27 March); https://www.jto.org/article/S1556-0864(21)02022-0/fulltext#:~:text=Conclusions%3A%20The%20incidence%20of%20de,diagnosis%20of%20stage%204%20NSCLC
Czubak K, Lewandowska MA, Klonowska K et al (2015) High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer. Oncotarget 6(27):23399–23416. https://doi.org/10.18632/oncotarget.4351
Diener C, Keller A, Meese E (2022) Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Gen 38(6):613–626. https://doi.org/10.1016/j.tig.2022.02.006
Duréndez-Sáez E, Torres-Martinez S, Calabuig-Fariñas S, Meri-Abad M, Ferrero-Gimeno M, Camps C (2021) Exosomal microRNAs in non-small cell lung cancer. Transl Cancer Res 10(6):3128–3139. https://doi.org/10.21037/tcr-20-2815
Feng B, Wang R, Song HZ, Chen LB (2012a) MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 118(13):3365–3376. https://doi.org/10.1002/cncr.26560
Feng B, Wang R, Chen LB (2012b) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 317(2):184–191. https://doi.org/10.1016/j.canlet.2011.11.024
Feng R, Patil S, Zhao X, Miao Z, Qian A (2021) RNA therapeutics - research and clinical advancements. Front Mol Biosci 8(710738):1–13. https://doi.org/10.3389/fmolb.2021.710738
Florczuk M, Szpechcinski A, Chorostowska-Wynimko J (2017) miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: current perspectives. Targ Oncol 12:179–200. https://doi.org/10.1007/s11523-017-0478-5
Francisco LM, Salinas VH, Brown KE et al (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015–3029
Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T et al (2015) The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther 23:717–727. https://doi.org/10.1038/mt.2015.10
Gebert LFR, MacRae IJ (2019) Regulation of microRNA function in animals. Nat Rev Mol Cell Biol 20:21–37. https://doi.org/10.1038/s41580-018-0045-7
Gong J, Shen Y, Jiang F, Wang Y, Chu L, Sun J et al (2022) MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating PD-L1 by targeting PTEN. Oncol Lett 23:148. https://doi.org/10.3892/ol.2022.13269
Grigg C, Rizvi NA (2016) PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer 4:48. https://doi.org/10.1186/s40425-016-0153-x
Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland A (2018) Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol 57(9):1225–1231. https://doi.org/10.1080/0284186X.2018.1465585
Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R (2009) Direct cell reprogramming is a stochastic process amenable to acceleration. Nat 462:595–601. https://doi.org/10.1038/nature08592
Holleman A, Chung I, Olsen RR et al (2011) miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30(43):4386–4398. https://doi.org/10.1038/onc.2011.148
Hong DS, Kang YK, Borad M et al (2020) Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumors. Br J Cancer 122:1630–1637. https://doi.org/10.1038/s41416-020-0802-1
Hu Z, Chen X, Zhao Y et al (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28(10):1721–1726. https://doi.org/10.1200/JCO.2009.24.9342
Huang W (2017) MicroRNAs: biomarkers, diagnostics, and therapeutics. Methods Mol Biol 1617:57–67. https://doi.org/10.1007/978-1-4939-7046-9_4
Ishii T, Fujishiro M, Masuda M, Teramoto S, Matsuse T (2004) A methylated oligonucleotide induced methylation of GSTP1 promoter and suppressed its expression in A549 lung adenocarcinoma cells. Cancer Lett 212(2):211–223. https://doi.org/10.1016/j.canlet.2004.03.001
Ishizu H, Siomi H, Siomi MC (2012) Biology of PIWI-interacting RNAs: new insights into biogenesis and function inside and outside of germlines. Genes Dev 26:2361–2373. https://doi.org/10.1101/gad.203786.112
Jiang M, Zhang WW, Liu P, Yu W, Liu T, Yu J (2017) Dysregulation of SOCS-mediated negative feedback of cytokine signaling in carcinogenesis and its significance in cancer treatment. Front Immunol 8(70):1–11. https://doi.org/10.3389/fimmu.2017.00070
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z (2019) Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 18:10. https://doi.org/10.1186/s12943-018-0928-4
Jindra PT, Bagley J, Godwin JG, Iacomini J (2010) Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. J Immunol 185:990–997. https://doi.org/10.4049/jimmunol.1000793
Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331,13
Khan P, Siddiqui JA, Lakshmanan I et al (2021) RNA-based therapies: a cog in the wheel of lung cancer defense. Mol Cancer 20:54. https://doi.org/10.1186/s12943-021-01338-2
Kim R (2007) Cancer immunoediting. In: Prendergast GC, Jaffee EM (eds) Cancer immunotherapy: immune suppression and tumor growth. Elsevier, London, UK, pp 19–25; Immunity to tumors (2007) In: Abbas AK, Lichtman AH, Pillai S (eds) Cellular and molecular immunology, 6th edn. Elsevier, Philadelphia, pp 397–417
Kim SM, Kim JS, Kim JH et al (2010) Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett 296(2):150–159. https://doi.org/10.1016/j.canlet.2010.04.006
Klimenko OV (2017) Joint action of the Nano-sized system of small non-coding RNAs with DDMC vector and recombinant IL-7 reprograms A-549 lung adenocarcinoma cells into CD4 + cells. Immunother (Los Angel) 3:1. https://doi.org/10.4172/2471-9552.1000137
Knosp CA, Schiering C, Spence S, Carroll HP, Nel HJ, Osbourn M, Jackson R, Lyubomska O, Malissen B, Ingram R et al (2013) Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2. J Immunol 190:3235–3245. https://doi.org/10.4049/jimmunol.1201396
Kotsakis A, Koinis F, Katsarou A et al (2016) Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep 6:39247. https://doi.org/10.1038/srep39247
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187. https://doi.org/10.1056/NEJMra044389
Lei L, Huang Y, Gong W (2013) MiR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep 30(6):2897–2902. https://doi.org/10.3892/or.2013.2755
Leidinger P, Galata V, Backes C et al (2015) Longitudinal study on circulating miRNAs in patients after lung cancer resection. Oncotarget 6(18):16674–16685. https://doi.org/10.18632/oncotarget.4322
Leidinger P, Brefort T, Backes C et al (2016) High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. Oncotarget 7(4):4611–4623. https://doi.org/10.18632/oncotarget.6566
Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134. https://doi.org/10.1016/j.cell.2010.06.011
Li J, Li X, Ren S et al (2014) miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget 5(17):7902–7916. https://doi.org/10.18632/oncotarget.2302
Li W, Wang Y, Zhang Q et al (2015) MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One 10(8):e0134220. https://doi.org/10.1371/journal.pone.0134220
Liu T-C, Jin X, Wang Y, Wang K (2017) Role of epidermal growth factor receptor in lung cancer and targeted therapies. AmJCancer Res 7(2):187–202
Liu X, Tang C, Song X, Cheng L, Liu Y, Ding F, Xia C, Xue L, Xiao J, Huang B (2020a) Clinical value of CTLA4-associated microRNAs combined with inflammatory factors in the diagnosis of non-small cell lung cancer. Ann Clin Biochem 57(2):151–161. https://doi.org/10.1177/0004563220901564
Liu L, Wang Q, Qiu Z et al (2020b) Noncoding RNAs: the shot callers in tumor immune escape. Sig Transduct Target Ther 5:102. https://doi.org/10.1038/s41392-020-0194-y
Lu LF et al (2009) Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30:80–91. https://doi.org/10.1016/j.immuni.2008.11.010
Lu LF et al (2010) Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142:914–929. https://doi.org/10.1016/j.cell.2010.08.012
Lu J, Zhan Y, Feng J, Luo J, Fan S (2018a) MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci 14(4):390–397. https://doi.org/10.7150/ijbs.22243
Lu J, Zhan Y, Feng J, Luo J, Fan S (2018b) MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci 14(4):390–397. https://doi.org/10.7150/ijbs.22243
Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58:903–913. https://doi.org/10.1016/j.ijrobp.2003.06.002
Muthu V, Mylliemngap B, Prasad KT, Behera D, Singh N (2019) Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting. Lung India 36(1):32–37. https://doi.org/10.4103/lungindia.lungindia_321_17
Namdari H, Ghayedi M, Hadjati J, Rezaei F, Kalantar K, Rahimzadeh P, Salehi E (2017) Effect of MicroRNA-21 transfection on in-vitro differentiation of human naive CD4+ T cells to regulatory t cells. Iran J Allergy Asthma Immunol 16:235–244
Nishikawa S, Ishii H, Haraguchi N, Kano Y, Fukusumi T, Ohta K, Ozaki M, Dewi DL, Sakai D, Satoh T et al (2012) MicroRNA-based cancer cell reprogramming technology. Exp Ther Med 4:8–14. https://doi.org/10.3892/etm.2012.558
Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847–856. https://doi.org/10.1158/1535-7163.MCT-14-0983
Paulsen EE, Kilvaer TK, Khanehkenari MR, Al-Saad S, Hald SM, Andersen S, Richardsen E, Ness N, Busund LT, Bremnes RM, Donnem T (2017) Assessing PDL-1 and PD-1 in non-small cell lung cancer: a novel Immunoscore approach. Clin Lung Cancer 18:220–233. https://doi.org/10.1016/j.cllc.2016.09.009
Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, Podhorska-Okolow M, Dziegiel P, Nowinska K (2019) Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to Clinicopathological factors and diagnostic markers. Int J Mol Sci 20(4):824. https://doi.org/10.3390/ijms20040824
Peschansky VJ, Wahlestedt C (2014) Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics 9:3–12. https://doi.org/10.4161/epi.27473
Petrek H, Batra N, Ho PY et al (2019) Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs. Appl Microbiol Biotechnol 103:6107–6117. https://doi.org/10.1007/s00253-019-09934-5
Poghosyan H, Sheldon LK, Leveille SG, Cooley ME (2013) Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. Lung Cancer 81(1):11–26. https://doi.org/10.1016/j.lungcan.2013.03.013
Ponomaryova AA, Morozkin ES, Rykova EY et al (2016) Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer. Exp Lung Res 42(2):95–102. https://doi.org/10.3109/01902148.2016.1155245
Qin A, Wen Z, Zhou Y, Li Y, Li Y, Luo J, Ren T, Xu L (2013a) MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway. J Cell Mol Med 17:252–264. https://doi.org/10.1111/jcmm.12003
Qin A, Wen Z, Zhou Y, Li Y, Li Y, Luo J, Ren T, Xu L (2013b) MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway. J Cell Mol Med 17:252–264. https://doi.org/10.1111/jcmm.12003
Qin Q, Wei F, Zhang J, Wang X, Li B (2016) miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor. J Cell Mol Med 20:1974–1983. https://doi.org/10.1111/jcmm.12889
Rajakumar T, Horos R, Jehn J et al (2022) A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. NPJ Precis Onc 6(19):1–13. https://doi.org/10.1038/s41698-022-00262-y
Rama AR, Perazzoli G, Cabeza L, Mesas C, Quiñonero F, García-Pinel B, Vélez C (2020) Novel MicroRNA sponges to specifically modulate gene expression in colon cancer cells. Nucleic Acid Ther 30(5):325–334. https://doi.org/10.1089/nat.2020.0861
Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJB, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N (2013) Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol 24(12):3128–3135. https://doi.org/10.1093/annonc/mdt412
Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, Boyer M, van Zandwijk N (2016) Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 8(8):1079–1085. https://doi.org/10.2217/epi-2016-0035
Ren P, Gong F, Zhang Y, Jiang J, Zhang H (2016) MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN. Tumour Biol 37(3):3215–3225. https://doi.org/10.1007/s13277-015-4150-3
Sacher AG, Gandhi L (2016) Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review JAMA. Oncologia 2:1217–1222. https://doi.org/10.1001/jamaoncol.2016.0639
Schvartsman G, Ferrarotto R, Massarelli E (2016) Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol 8(6):460–473. https://doi.org/10.1177/1758834016661164
Seo HA, Moeng S, Sim S, Kuh HJ, Choi SY, Park JK (2020) MicroRNA-based combinatorial cancer therapy: effects of MicroRNAs on the efficacy of anti-cancer therapies. Cell 9(1):29. https://doi.org/10.3390/cells9010029
Shen Y, Tang D, Yao R et al (2013) microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol 30(4):750. https://doi.org/10.1007/s12032-013-0750-1
Shen H, Wang L, Ge X, Jiang CF et al (2016) MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer. Oncotarget 7(15):20728–20742. https://doi.org/10.18632/oncotarget.8011
Shimada K, Serada S, Fujimoto M, Nomura S, Nakatsuka R, Harada E, Iwahori K, Tachibana I, Takahashi T, Kumanogoh A, Kishimoto T, Naka T (2013) Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Cancer Sci 104(11):1483–1491. https://doi.org/10.1111/cas.12266
Siegelin MD, Borczuk AC (2014) Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Investig 94:129–137. https://doi.org/10.1038/labinvest.2013.147
Subarmanian S, Steer CJ (2019) Special issue: MicroRNA regulation in health and disease. Genes 10(6):457. https://doi.org/10.3390/genes10060457
Takahashi R, Yoshimura A (2014) SOCS1 and regulation of regulatory T cells plasticity. J Immunol Res 9431492014. https://doi.org/10.1155/2014/943149
Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I (2008) MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nat 455:1124–1128. https://doi.org/10.1038/nature07299
Tian T, Shu Y, Chen J et al (2009) A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomark Prev 18(4):1183–1187. https://doi.org/10.1158/1055-9965.EPI-08-0814
Van Roosbroeck K, Calin GA (2017) Chapter four—cancer hallmarks and MicroRNAs: the therapeutic connection. In: Croce CM, Fisher PB (eds) Advances in cancer research, vol 135. Academic Press, Cambridge, MA, USA, pp 119–149
van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G (2017) Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 18(10):1386–1396. https://doi.org/10.1016/S1470-2045(17)30621-6
Walsh PT, Buckler JL, Zhang J et al (2006) PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs. J Clin Invest 116:2521–2531. https://doi.org/10.1172/JCI28057
Wan J, Ling X, Peng B, Ding G (2018) miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway Oncol rep. 40:272-282. https://doi.org/10.3892/or.2018.6439
Wang N, Zhang T (2018) Downregulation of MicroRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16. Oncol Res 26:1005–1014. https://doi.org/10.3727/096504017X15144755633680
Wang L, Pino-Lagos K, de Vries VC et al (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci 105:9331–9336
Wang XC, Du LQ, Tian LL et al (2011) Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 72(1):92–99. https://doi.org/10.1016/j.lungcan.2010.07.014
Wang Y, Sun T, Wang K, Wang J-X, Li PF (2014) PiRNAs link epigenetic modifications to reprogramming. Histol Histopathol 29:1–9. https://doi.org/10.14670/HH-29.1489
Wang S, Su X, Bai H et al (2015) Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. J Hematol Oncol 8:127. https://doi.org/10.1186/s13045-015-0210-9
Wang S, Xu L, Che X, Li C, Xu L, Hou K, Fan Y, Wen T, Qu X, Liu Y (2018) E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer. FEBS Lett 592:621–630. https://doi.org/10.1002/1873-3468.12985
Wu KL, Tsai YM, Lien CT, Kuo PL, Hung AJ (2019) The roles of MicroRNA in lung cancer. Int J Mol Sci 20(7):1611. https://doi.org/10.3390/ijms20071611
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y et al (2014) miR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33:378–386. https://doi.org/10.1038/onc.2012.575
Xie X, Liu HT, Mei J, Ding FB, Xiao HB, Hu FQ et al (2015) MiR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. Int J Clin Exp Pathol 8(4):3827–3834
Xie WB, Liang LH, Wu KG, Wang LX, He X, Song C, Wang YQ, Li YH (2018) MiR-140 expression regulates cell proliferation and targets PD-L1 in NSCLC. Cell Physiol Biochem 46:654–663. https://doi.org/10.1159/000488634
Xing Y, Wang Z, Lu Z, Xia J, Xie Z, Jiao M, Liu R, Chu Y (2021) MicroRNAs: immune modulators in cancer immunotherapy. Immunother Adv 1(1):ltab006. https://doi.org/10.1093/immadv/ltab006
Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han L et al (2013) MicroRNA-155 expression has prognostic value in patients with non-small cell. Lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev 14(12):7085–7090. https://doi.org/10.7314/apjcp.2013.14.12.7085
Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X et al (2016a) MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget 7(51):84508–8451952. https://doi.org/10.18632/oncotarget.13022
Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, Zhao S, Sun X, Cui L, Pan L, Liu S (2016b) MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget 7(51):84508–84519. https://doi.org/10.18632/oncotarget.13022
Yang HY, Barbi J, Wu CY, Zheng Y, Vignali PD, Wu X, Tao JH, Park BV, Bandara S, Novack L et al (2016) MicroRNA-17 modulates regulatory T cell function by targeting co-regulators of the Foxp3 transcription factor. Immunity 45:83–93. https://doi.org/10.1016/j.immuni.2016.06.022
Ye J, Zhang Z, Sun L, Fang Y, Xu X, Zhou G (2016) miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol BioSyst 12(11):3417–3424. https://doi.org/10.1039/c6mb00576d
Yin Y, Cai X, Chen X et al (2014) Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res 24:1164–1180. https://doi.org/10.1038/cr.2014.121
Yuan Z, Zeng X, Yang D, Wang W, Liu Z (2013) Effects of common polymorphism rs11614913 in Hsa-miR-196a2 on lung cancer risk. PLoS One 8(4):e61047. https://doi.org/10.1371/journal.pone.0061047
Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ (2011) MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6(4):671–678. https://doi.org/10.1097/JTO.0b013e318208eb35
Zhang X, Zhu J, Xing R et al (2012) miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer 77(3):488–494. https://doi.org/10.1016/j.lungcan.2012.05.107
Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B (2013) Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. PLoS One 8(11):e81408
Zhang S, Cheng Z, Wang Y, Han T (2021) The risks of miRNA therapeutics: in a drug target perspective. Drug Des Devel Ther 15:721–733. https://doi.org/10.2147/DDDT.S288859
Zhang Z, Huang Q, YuL ZD, Li Y, Xue Z, Hua Z, Luo X, Song Z, Lu C, Zhao T, Liu Y (2022a) The role of miRNA in tumor immune escape and miRNA-based therapeutic strategies. Front Immunol:1–14. https://doi.org/10.3389/fimmu.2021.807895
Zhang W, Zhang Q, Che L et al (2022b) Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer. BMC Cancer 22:299. https://doi.org/10.1186/s12885-022-09281-1
Zhao Q, Cao J, Wu Y-C et al (2015) Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. Am J Cancer Res 5(5):1692–1705
Zhou Y, Li Y, Lu J, Hong X, Xu L (2019) MicroRNA-30a controls the instability of inducible CD4+ Tregs through SOCS1. Mol Med Rep 20:4303–4314. https://doi.org/10.3892/mmr.2019.10666
Zhou C, Lia M, Wang Z, An D, Li B (2022) Adverse events of immunotherapy in non-small cell lung cancer: a systematic review and network meta-analysis. Int Immunopharmacol 102(108353):1–10. https://doi.org/10.1016/j.intimp.2021.108353
Zhu K, Ding H, Wang W, Liao Z, Fu Z, Hong Y, Zhou Y, Zhang CY, Chen X (2016) Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer. Oncotarget 7:28075–28085. https://doi.org/10.18632/oncotarget.8576
Zhu L, Liu J, Wang L, Yan D, Zhou J, Li W, Pu D, Peng L, Zhou Q (2020) Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathol Res Pract 216(4):152852. https://doi.org/10.1016/j.prp.2020.152852
Acknowledgments
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that there is no conflict of interest.
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Klimenko, O.V., Sidorov, A. (2022). MicroRNAs in the Immunopathology and Treatment of Non-small Cell Lung Cancer. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2022_53
Download citation
DOI: https://doi.org/10.1007/16833_2022_53
Published:
Publisher Name: Springer, Cham